These data suggest that RSV may be useful in improving the immune recognition of malignant B cells by CD4+ T lymphocytes, opening an interesting perspective for the immunochemotherapy of B-cell lymphomas. Here, CD4 is linked to B-cell non-Hodgkin lymphoma.